Overview

Study of the Efficacy and Safety of Tesevatinib in Subjects With ADPKD

Status:
Active, not recruiting
Trial end date:
2022-01-31
Target enrollment:
Participant gender:
Summary
The goal of the study is to compare and evaluate safety and efficacy of tesevatinib 50mg versus placebo in patients with ADPKD.
Phase:
Phase 2
Details
Lead Sponsor:
Kadmon Corporation, LLC
Treatments:
XL647